Eric Dein ericdeinmd
4 years ago
#ACR21. Powerful patient perspective by Amy Barron, RN and rheumatic patient
⭐️"I found hope advocating for arthritis" and found meaning in advocacy.
▶️ Consider talking to your patients about getting involved in ACR Advocacy to give purpose & community.
@ACRheumDC @CreakyJoints https://t.co/2mJRaShZQQ
Dr. Rachel Tate uptoTate
4 years ago
Females axSpA pts presented w/ higher disease burden (fatigue/tiredness, & spinal pain at night.) Female axSpA pts achieved sign/symptom improvement with IXE later than male axSpA pts. Abs 0934 #ACR21 #RheumNow@RheumNow https://t.co/EGXnfeF6KQ https://t.co/TDF5zxtca7
Bella Mehta bella_mehta
4 years ago
Oral Calcitonin not recommended for OA - studies did not show efficacy
Strontium Ranelate study below was considered a positive study in KOA with efficacy but had Cardiovascular toxicity - now off the market. https://t.co/gcYH9xoxeo
Bella Mehta bella_mehta
4 years ago
Wnt signaling - Lorecivivint is now in phase 3 https://t.co/JSk2nPBTrI
Akhil Sood MD AkhilSoodMD
4 years ago
Abst 0789
Baker & colleagues examined adipokine levels in association with disease activity in RA patients
- Patients with high levels of adipokines less likely to achieve low disease activity & remission
- These patients more likely to escalate to b/tsDMARDs
#ACR21 @RheumNow https://t.co/1xlO4W9q9v
Akhil Sood MD AkhilSoodMD
4 years ago
Another exciting day at #ACR21 and covering for @RheumNow
Also presented my poster (Abstr 0587) DMARD Use in Medicare Patients with #RheumatoidArthritis and Risk of Long-Term Opioid Use
- DMARD users showed lower odds of long term opioid use compared to non-DMARD users https://t.co/2XZgYY8ORg
Meral K. El Ramahi, MD MeralElRamahiMD
4 years ago
Great time recapping D2 of ACR live with my fellow RheumNow Faculty! @RheumNow @drdavidliew @doctorRBC @DrMiniDey @swethaann23
Check it out here: https://t.co/4IcjkIlEb6
Be sure to keep tuning into https://t.co/nVnVgigOKL for more captivating coverage of #ACR21! https://t.co/Je6GxoBgiy
Janet Pope Janetbirdope
4 years ago
As old saying but updated goes: Wise man/woman/prefer not to answer says IF you STOP drugs they usually STOP working. True with TNFi in most diseases (RA, axSpA, etc). Also tue with #plaquenil in large #SLE study #ACR21 abst#0959 https://t.co/O6Ejg5sjjK
sheila RHEUMarampa
4 years ago
Recaps on highlights! This was fun!🤓
#ICYMI #ACR21 @RheumNow https://t.co/e7EjaDAzQ7
Pedro Castillo _Castillo_Pedro
4 years ago
@RheumNow From Abst#3053 noted above, here we see the trend of urinary ALCAM with UPCr and renal-SLEDAI https://t.co/3Ujo8WTslO
Pedro Castillo _Castillo_Pedro
4 years ago
Stopping/reducing hydroxychloroquine (HCQ) in SLE associated with increased flares, especially for those in low disease activity or in remission. Super helpful data to share with pts wanting to reduce/dc HCQ.
#ACR21 Abst#0959 Plenary Session II @RheumNow https://t.co/i7jPDN2sgZ
sheila RHEUMarampa
4 years ago
Dr FCardwell et al on Health Info use in SLE pts b4 and during COVID19 using an online survey
🦋#lupus specialists & fam physicians - ⬆preferred & trusted health info sources but access to them ⬇frequent during covid19
A call to action?📢
@RheumNow #ACR21 abs0880 @rheumarhyme https://t.co/1NBEAlFvHx
Pedro Castillo _Castillo_Pedro
4 years ago
AS and PsA: Mortality vs Gen Pop (meta-analysis)
AS:
👉⬆️All-cause
👉⬆️CVD
PsA:
👉All-cause not higher
👉⬆️CVD, Respiratory, and Infectious etiologies
Important to consider CVD and other comorbidities.
https://t.co/9K4qNpYvMb
#ACR21 Abst#0569 @RheumNow
David Liew drdavidliew
4 years ago
We know we're all not as great at treat-to-target in RA as we should be.
If we want to get fit, we join a group class.
If we want to study, we join a study group.
Why not the same with TTT, to motivate us to our best?
Virtual learning collaboratives 👏
#ACR21 ABST0815 @RheumNow https://t.co/siVOyKjPNx
TheDaoIndex KDAO2011
4 years ago
Awesome interview w/ @rheum_cat @JYazdanyMD @jeffsparks
video link https://t.co/dVLayNchHT


Poster Hall